Welcome to ProAxsis

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease, using its patented ProteaseTag® technology.

ProAxsis specialises in four key areas of business:-

 

 

 

 

 

 

     
     

News

ProAxsis provides update on commercialisation progress
Having reached the first anniversary following relocation to its new purpose-built laboratory on the Ca...
ProAxsis to showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference
ProAxsis will be presenting further data on its ProteaseTag® technology, at the North American Cystic ...
ProAxsis to test ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease at National Jewish Health
ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in ...
ProAxsis appoints first distributor for NE Immunoassay
ProAxsis today announces that the company has appointed Diagenics Limited as the distributor for its Pr...
Proaxsis